Has Stephen Miller, MD received payments from drug or device companies?

Yes. Drug and device makers reported $94,638 in general payments to Stephen Miller, MD across 402 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Miller, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Miller, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Miller, MD

Cardiovascular Disease · Murray, UTNPI 1578514477

Payments from drug & device makers

$94,638in general payments, 2019–2025

Across 402 payments — averaging $235.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Akcea Therapeutics, Inc.$47K
American Regent$36K
E.r. Squibb & Sons, L.L.C.$3K
Boston Scientific$2K
Amgen$751
Novartis$745
plus $5K from 40 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Akcea Therapeutics, Inc.	9	$47,490
American Regent	14	$36,295
E.r. Squibb & Sons, L.L.C.	44	$2,691
Boston Scientific	35	$2,005
Amgen	37	$751
Novartis	56	$745
Boehringer Ingelheim	37	$631
Biotronik Inc.	1	$605
Pfizer	29	$550
Merck	30	$538
Kiniksa Pharmaceuticals International, PLC	9	$246
Johnson & Johnson	13	$222
Abbott	8	$190
Bayer	7	$122
Braemar Manufacturing, LLC	1	$119
Kowa Pharmaceuticals America, Inc.	7	$107
Impulse Dynamics (USA) Inc.	4	$105
Cvrx, Inc.	4	$105
Amarin Pharma, Inc.	7	$104
Lundbeck LLC	5	$95
Scpharmaceuticals Inc.	4	$91
Lexicon Pharmaceuticals, Inc.	3	$91
Coala Life Inc	1	$85
AstraZeneca	5	$64
Kiniksa Pharmaceuticals, Ltd.	2	$53
Edwards Lifesciences	2	$48
Esperion Therapeutics, Inc.	3	$44
Novo Nordisk	2	$41
Varian Medical Systems, Inc.	2	$37
Stryker	1	$35
Gilead	2	$29
Regeneron Healthcare Solutions, Inc.	2	$28
Lantheus Medical Imaging, Inc.	1	$27
Azurity Pharmaceuticals, Inc.	2	$27
Bardy Diagnostics, Inc.	2	$27
Alnylam Pharmaceuticals Inc.	1	$25
Optinose US, Inc.	1	$24
Baxter Healthcare	1	$20
Sanofi-aventis U.S. LLC	1	$18
Sanofi	1	$18
Itamar Medical Inc	1	$17
Actelion Pharmaceuticals US, Inc.	1	$17
Inogen, Inc.	1	$15
Aegerion Pharmaceuticals, Inc.	1	$13
Qorumpartners	1	$13
Medicure Pharma Inc.	1	$12

How this compares

$94,638 in reported general payments places this provider in the 80th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah →

Medicare billing

Part B allowed, 2024

$866,594

Medicare patients

959

Services billed

13,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Murray

Brian WhisenantMurray$3.4M
Divya Ratan VermaMurray$1.1M
Kia AfsharMurray$442K
Rami AlharethiMurray$403K
Joseph MuhlesteinMurray$308K
James OrfordMurray$98K
Kirk KnowltonMurray$53K
Travis MossMurray$6K
Jonathan HarrisonMurray$5K
Alpana SenapatiMurray$4K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →